©The Author(s) 2025.
World J Transplant. Dec 18, 2025; 15(4): 104349
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.104349
Published online Dec 18, 2025. doi: 10.5500/wjt.v15.i4.104349
Table 6 Diagnostic performance of donor-specific antibodies, donor-derived cell-free DNA and combination of donor-specific antibodies and donor-derived cell-free DNA for detecting rejection, antibody-mediated rejection and severe microvascular inflammation
| Characteristics | Rejection | ABMR | Severe MVI | |||
| Sensitivity (%) (95%CI) | Specificity (%) (95%CI) | Sensitivity (%) (95%CI) | Specificity (%) (95%CI) | Sensitivity (%) (95%CI) | Specificity (%) (95%CI) | |
| DSA | 62.5 | 63.3 | 90.0 | 83.3 | 50.0 | 78.0 |
| dd-cfDNA | 93.8 | 58.3 | 90.0 | 51.9 | 92.9 | 56 |
| dd-cfDNA (> 1.0%) | 50 | 83.3 | 60 | 81.5 | 78.6 | 90 |
| DSA or dd-cfDNA (> 0.4%) | 100 | 50 | 100 | 44.4 | 92.9 | 46 |
| DSA and dd-cfDNA (> 0.4%) | 56.3 | 91.7 | 80 | 90.7 | 50 | 88 |
- Citation: Salvadori M, Rosso G. Utility and limitations of the use of donor-derived cell-free DNA in kidney transplantation. World J Transplant 2025; 15(4): 104349
- URL: https://www.wjgnet.com/2220-3230/full/v15/i4/104349.htm
- DOI: https://dx.doi.org/10.5500/wjt.v15.i4.104349